Abstract
Purpose Opioid overdose remains a problem in the United States despite pharmacotherapies, such as buprenorphine, in the treatment of opioid use disorder (OUD). This study characterized changes in buprenorphine use.
Methods Using the Drug Enforcement Administration’s ARCOS, Medicaid and Medicare claims databases, patterns in buprenorphine usage in the United States from 2018 to 2020 were analyzed by examining percentage changes in total grams distributed and changes in grams per 100K people in year-to-year usage based on zip-code and state levels.
Results For ARCOS from 2018-19 and 2019-20, total buprenorphine distribution in grams increased 16.2% and 12.6% respectively. South Dakota showed the largest state-wide percentage increase in both 2018-19 (66.1%) and 2019-20 (36.7%). From 2018-19, the zip codes ND-577 (156.4%) and VA-222 (−82.1%) had the largest and smallest percentage changes respectively. From 2019-20, CA-932 (250.2%) and IL-603 (−36.8%) were the largest and smallest respectively. In both 2018-19 and 2019-20, PA-191 had the second highest increase in grams per 100K while OH-452 was the only zip code to remain in the top 3 largest decreases in grams per 100K in both periods. Among Medicaid patients in 2018, there was a 1,932.1-fold difference in prescriptions per 100k Medicaid enrollees between Kentucky (12,075.5) and Nebraska (6.25). Among Medicare enrollees in 2018, family medicine physicians and other primary care providers were the top buprenorphine prescribers.
Conclusions This study identified overall increases in buprenorphine availability but also pronounced state-level differences. Such geographic analysis can be used to discern which public policies and regional factors impact buprenorphine access.
Key Points
Total buprenorphine distribution in grams increased 16.2% and 12.6% for 2018-2019 and 2019-2020 ARCOS data, respectively
On a state level, from 2020-21, the majority of states were decreasing buprenorphine distribution as reported by ARCOS
The state with the highest buprenorphine usage among Medicaid patients in both 2018 and 2019 was Kentucky
Family medicine physicians were the top buprenorphine prescribers to Medicare enrollees in 30 states
Maine had the largest number of buprenorphine prescriptions to Medicare enrollees
Plain Language Summary Opioid overdose remains a problem in the United States despite medical therapy, such as buprenorphine, in the treatment of opioid use disorder (OUD). This study aimed to describe changes in buprenorphine use. Using the Drug Enforcement Administration’s ARCOS, Medicare, and Medicaid databases, patterns in buprenorphine usage in the United States from 2018 to 2020 were analyzed based on zip-code and state levels. For ARCOS from 2018-19 and 2019-20, total buprenorphine distribution in grams increased 16.2% and 12.6% respectively.South Dakota showed the largest state-wide percentage increase in both 2018-19 (66.1%) and 2019-20 (36.7%). From 2018-19, the zip codes ND-577 (156.4%) and VA-222 (−82.1%) had the largest and smallest percentage changes respectively. From 2019-20, CA-932 (250.2%) and IL-603 (−36.8%) were the largest and smallest respectively. Among Medicaid patients in 2018, there was a 1,932.1-fold difference in prescriptions per 100k Medicaid enrollees between Kentucky (12,075.5) and Nebraska (6.25). Among Medicare enrollees in 2018, family medicine physicians and other primary care providers were the top buprenorphine prescribers. This study found overall increases in buprenorphine availability but also pronounced state-level differences. Such geographic analysis can be used to determine which public policies and regional factors impact access to buprenorphine.
Ethics Statement Hereby, I Justina A. Warnick consciously assure that for the manuscript “An Analysis of Patterns of Distribution of Buprenorphine in the United States using ARCOS, Medicaid, and Medicare Databases” the following is fulfilled:
This material is the authors’ own original work, which has not been previously published elsewhere aside from preprint server MedRxiv.
The paper is not currently being considered for publication elsewhere.
The paper reflects the authors’ own research and analysis in a truthful and complete manner.
The paper properly credits the meaningful contributions of co-authors and co-researchers.
The results are appropriately placed in the context of prior and existing research.
All sources used are properly disclosed (correct citation). Literally copying of text must be indicated as such by using quotation marks and giving proper reference.
All authors have been personally and actively involved in substantial work leading to the paper and will take public responsibility for its content.
I acknowledge that the violation of the Ethical Statement rules may result in severe consequences.
Competing Interest Statement
BJP was (2019-2021) part of an osteoarthritis research team supported by Pfizer and Eli Lilly.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ARCOS, Medicaid, and Medicare databases
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Prior Presentations: The findings from this manuscript have been previously presented in poster format at the Geisinger Commonwealth School of Medicine Spring Student Research Symposium in Scranton, PA in April 2021. A preprint was submitted to MedRxiv on 8/22/2022.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
